Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2026 | 94 | 2.930 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2026 | 165 | 2.120 |
Why?
|
| Consensus | 4 | 2024 | 76 | 1.450 |
Why?
|
| HIV Infections | 2 | 2022 | 165 | 1.290 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 64 | 0.860 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 485 | 0.840 |
Why?
|
| Neoplasms | 4 | 2025 | 887 | 0.840 |
Why?
|
| Palliative Care | 1 | 2022 | 87 | 0.700 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2021 | 40 | 0.690 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 13 | 0.690 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2023 | 70 | 0.670 |
Why?
|
| Proton Therapy | 1 | 2021 | 29 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 349 | 0.650 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 147 | 0.610 |
Why?
|
| Humans | 26 | 2026 | 29202 | 0.520 |
Why?
|
| Cisplatin | 2 | 2026 | 186 | 0.420 |
Why?
|
| Delphi Technique | 2 | 2024 | 25 | 0.420 |
Why?
|
| Endpoint Determination | 2 | 2024 | 18 | 0.420 |
Why?
|
| Cancer Survivors | 2 | 2025 | 72 | 0.420 |
Why?
|
| HIV | 2 | 2022 | 12 | 0.380 |
Why?
|
| Radiotherapy Dosage | 5 | 2024 | 109 | 0.340 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2021 | 63 | 0.330 |
Why?
|
| Exercise | 2 | 2025 | 502 | 0.330 |
Why?
|
| Chemoradiotherapy | 3 | 2026 | 50 | 0.330 |
Why?
|
| Middle Aged | 8 | 2025 | 7493 | 0.270 |
Why?
|
| Terminology as Topic | 2 | 2024 | 64 | 0.250 |
Why?
|
| Quality of Life | 3 | 2025 | 523 | 0.250 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2026 | 33 | 0.240 |
Why?
|
| Female | 11 | 2025 | 15819 | 0.230 |
Why?
|
| Male | 8 | 2025 | 14120 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2024 | 12 | 0.230 |
Why?
|
| Occupational Therapy | 1 | 2025 | 38 | 0.220 |
Why?
|
| Cetuximab | 1 | 2024 | 22 | 0.220 |
Why?
|
| Smartphone | 1 | 2025 | 85 | 0.210 |
Why?
|
| Brachytherapy | 2 | 2022 | 54 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 177 | 0.200 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 22 | 0.200 |
Why?
|
| Aged | 5 | 2025 | 5647 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 480 | 0.200 |
Why?
|
| Carcinoma | 1 | 2024 | 74 | 0.190 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2023 | 21 | 0.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2022 | 13 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 336 | 0.190 |
Why?
|
| Thyroid Gland | 1 | 2022 | 32 | 0.190 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 40 | 0.190 |
Why?
|
| Retinal Detachment | 1 | 2022 | 11 | 0.180 |
Why?
|
| Eye Neoplasms | 1 | 2022 | 8 | 0.180 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 80 | 0.180 |
Why?
|
| Carboplatin | 1 | 2022 | 121 | 0.180 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2022 | 4 | 0.180 |
Why?
|
| Pyridazines | 1 | 2022 | 8 | 0.180 |
Why?
|
| Radiation Injuries | 1 | 2022 | 52 | 0.180 |
Why?
|
| Quinazolines | 1 | 2022 | 32 | 0.180 |
Why?
|
| Prognosis | 1 | 2024 | 817 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 346 | 0.180 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 303 | 0.180 |
Why?
|
| Retinal Diseases | 1 | 2022 | 47 | 0.170 |
Why?
|
| Paclitaxel | 1 | 2022 | 201 | 0.170 |
Why?
|
| Metal Nanoparticles | 1 | 2023 | 137 | 0.170 |
Why?
|
| Macular Degeneration | 1 | 2022 | 86 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2024 | 2659 | 0.170 |
Why?
|
| Intraoperative Care | 1 | 2020 | 23 | 0.160 |
Why?
|
| Melanoma | 1 | 2022 | 140 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2020 | 20 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2022 | 171 | 0.160 |
Why?
|
| Breast | 1 | 2020 | 52 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2026 | 686 | 0.160 |
Why?
|
| Radiation Oncology | 2 | 2024 | 20 | 0.160 |
Why?
|
| Mammography | 1 | 2021 | 83 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 360 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 305 | 0.140 |
Why?
|
| Conjunctival Neoplasms | 1 | 2018 | 6 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2018 | 9 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 216 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2020 | 1287 | 0.130 |
Why?
|
| Obesity | 1 | 2021 | 705 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2021 | 2442 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 22 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2025 | 165 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 70 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 101 | 0.100 |
Why?
|
| Decision Making | 1 | 2014 | 179 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 484 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 1021 | 0.080 |
Why?
|
| Adult | 3 | 2024 | 8125 | 0.070 |
Why?
|
| Urban Population | 1 | 2025 | 97 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 233 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 42 | 0.050 |
Why?
|
| Marijuana Use | 1 | 2024 | 44 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 140 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 467 | 0.050 |
Why?
|
| Cannabis | 1 | 2024 | 48 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2023 | 12 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2023 | 54 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2023 | 35 | 0.050 |
Why?
|
| Mice | 2 | 2023 | 4867 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 15 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 36 | 0.050 |
Why?
|
| Telemedicine | 1 | 2025 | 228 | 0.050 |
Why?
|
| Gold | 1 | 2023 | 137 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 80 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 903 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2022 | 212 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 276 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1066 | 0.040 |
Why?
|
| Animals | 2 | 2023 | 10802 | 0.030 |
Why?
|